EUDA
EUDA Health Holdings Limited
NasdaqCMUSDEQUITY
Real Estate
DELAYED
Buy
+47/100
Last price
19.04
▼ 0.11 (0.58%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
19.13
Prev close
19.15
Day high
20.20
Day low
18.25
Volume
10.41K
Market cap
$57.01M
P/E (TTM)
—
52W range
5.26 – 86.00
Day trading desk
Gap from prior close
-1.37%
Prior close 19.39
VWAP
19.46
-2.16% from price
Relative volume
0.67×
Normal
Session range
10.68%
18.25 – 20.20
Position in range
40%
Mid range
ATR (14D)
1.59
8.34% of price
Prior day high
19.76
PDH
Prior day low
17.10
PDL
Bid / ask spread
—
Quote not published
Session volume
9.25K
Avg 13.86K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+33.14%
+31.2%
1M
+41.66%
+40.2%
3M
+53.17%
+49.8%
6M
+171.99%
+157.0%
YTD
-58.79%
-72.8%
1Y
-59.66%
-75.4%
3Y
-41.60%
-123.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on EUDA open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
1.23M
Total on file
Fundamentals
Market cap$57.01M
Enterprise value$58.02M
Revenue (TTM)$7.23M
Gross profit$3.44M
EBITDA$-1.84M
Net income$-2.36M
EPS (TTM)$-1.16
Free cash flow$-8.80M
Total cash$365.90K
Total debt$339.99K
Book value / share$2.00
Shares outstanding2.99M
Float1.76M
Short % of float0.08%
Dividend yield0.00%
Beta (5Y)0.59
Valuation & profitability ratios
Trailing P/E—
Forward P/E11.90
PEG ratio—
Price / sales—
Price / book9.54
EV / revenue8.02
EV / EBITDA-31.49
Gross margin47.57%
Operating margin-21.96%
Profit margin-32.69%
Return on equity-211.36%
Return on assets-21.92%
Debt / equity5.70
Current ratio2.53
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $6.82M | $4.01M | $3.71M | $3.76M | — | +70.0% |
| Operating revenue | $6.82M | $4.01M | $3.71M | $3.76M | — | +70.0% |
| Cost of revenue | $3.83M | $3.25M | $2.86M | $2.89M | — | +17.8% |
| Gross profit | $2.99M | $762.15K | $842.08K | $870.00K | — | +292.7% |
| Research & development | $249 | $0 | $0 | $17.21K | — | — |
| Selling, general & admin | $5.43M | $3.34M | $4.80M | $6.75M | — | +62.6% |
| Total operating expense | $5.43M | $3.34M | $4.80M | $6.75M | — | +62.6% |
| Operating income | -$2.44M | -$2.58M | -$3.96M | -$5.88M | — | +5.4% |
| Net interest income | -$228.62K | -$44.89K | -$23.23K | -$93.78K | — | -409.3% |
| Pre-tax income | -$2.73M | -$17.64M | -$8.43M | -$25.03M | — | +84.5% |
| Tax provision | $41.94K | -$4.38K | $0 | -$20.79K | — | +1,057.6% |
| Net income | -$2.77M | -$15.36M | -$10.04M | -$24.88M | — | +81.9% |
| Net income to common | -$2.77M | -$15.36M | -$10.04M | -$24.88M | — | +81.9% |
| Basic EPS | — | -9.46 | -8.77 | -41.40 | 1.87 | — |
| Diluted EPS | — | -9.46 | -8.77 | -41.40 | 1.87 | — |
| EBIT | -$2.50M | -$17.60M | -$8.41M | -$24.93M | — | +85.8% |
| EBITDA | -$2.09M | -$17.42M | -$8.29M | -$24.76M | — | +88.0% |
| Basic shares | — | 1.62M | 1.15M | 601.48K | 462.67K | — |
| Diluted shares | — | 1.62M | 1.15M | 601.48K | 462.67K | — |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $345.14K | $237.60K | $189.00K | $57.54K | +45.3% |
| Cash & short-term investments | $345.14K | $237.60K | $189.00K | $57.54K | +45.3% |
| Accounts receivable | $242.61K | $146.17K | $237.47K | $192.85K | +66.0% |
| Inventory | $2.84K | $128.98K | $0 | — | -97.8% |
| Total current assets | $1.04M | $762.88K | $723.44K | $25.03M | +36.2% |
| Property, plant & equipment | $332.29K | $316.26K | $206.99K | $64.34K | +5.1% |
| Goodwill & intangibles | $161.43K | $337.30K | $0 | $0 | -52.1% |
| Total assets | $1.72M | $1.70M | $1.31M | $25.63M | +1.1% |
| Total current liabilities | $5.84M | $4.14M | $8.72M | $29.12M | +40.9% |
| Current debt | $2.20M | $1.04M | $3.17M | $3.57M | +111.3% |
| Total debt | $2.40M | $1.27M | $3.37M | $3.63M | +88.7% |
| Total liabilities | $5.98M | $4.27M | $8.79M | $29.14M | +40.1% |
| Retained earnings | -$52.87M | -$50.10M | -$34.74M | -$24.70M | -5.5% |
| Shareholder equity | -$4.25M | -$2.55M | -$7.50M | -$3.52M | -66.7% |
| Working capital | -$4.80M | -$3.38M | -$7.99M | -$4.09M | -42.0% |
| Net tangible assets | -$4.42M | -$2.89M | -$7.50M | -$3.52M | -52.8% |
| Shares issued | 1.89M | 1.86M | 1.23M | 1.12M | +1.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$2.77M | -$17.64M | -$8.43M | -$25.01M | — | +84.3% |
| Depreciation & amortisation | $406.48K | $173.22K | $119.35K | $172.02K | — | +134.7% |
| Change in working capital | -$230.03K | $194.93K | $531.20K | $2.79M | — | -218.0% |
| Operating cash flow | -$2.43M | -$2.03M | -$2.92M | -$1.53M | — | -19.3% |
| Capital expenditure | -$104.45K | -$116.03K | — | -$18.14K | -$1.10K | +10.0% |
| Investing cash flow | -$104.45K | -$147.77K | $0 | -$268.21K | — | +29.3% |
| Financing cash flow | $2.55M | $2.32M | $2.35M | $2.49M | — | +9.7% |
| Free cash flow | -$2.53M | -$2.15M | -$2.92M | -$1.53M | — | -17.7% |
| End cash position | $345.14K | $237.60K | $197.55K | $784.49K | — | +45.3% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
| Line item | 2025-12-31 | 2025-06-30 | YoY |
|---|---|---|---|
| Cash & equivalents | $345.14K | — | — |
| Cash & short-term investments | $345.14K | — | — |
| Accounts receivable | $242.61K | — | — |
| Inventory | $2.84K | — | — |
| Total current assets | $1.04M | — | — |
| Property, plant & equipment | $332.29K | — | — |
| Goodwill & intangibles | $161.43K | — | — |
| Total assets | $1.72M | — | — |
| Total current liabilities | $5.84M | — | — |
| Current debt | $2.20M | — | — |
| Total debt | $2.40M | — | — |
| Total liabilities | $5.98M | — | — |
| Retained earnings | -$52.87M | — | — |
| Shareholder equity | -$4.25M | — | — |
| Working capital | -$4.80M | — | — |
| Net tangible assets | -$4.42M | — | — |
| Shares issued | 1.89M | 1.86M | +1.8% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | 1.60 | 1 | $27.23M | +299.3% |
| Next year | — | — | $0 | — |
Analyst targets & ownership
Mean target$55.00
High target$55.00
Low target$55.00
Implied upside188.87%
Analyst count1
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders41.17%
Held by institutions0.00%
Institutions holding1
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
16.96
+12.29% from price
SMA 20
16.66
+14.26% from price
SMA 50
15.74
+20.95% from price
SMA 100
15.41
+23.56% from price
SMA 200
18.00
+5.80% from price
EMA 12
17.20
+10.70% from price
EMA 26
16.42
+15.95% from price
EMA 50
15.84
+20.24% from price
RSI (14)
62.0
Neutral
MACD (12,26,9)
0.78
Hist 0.23
ATR (14)
1.59
8.34% of price
Realised vol 30D
102.5%
Annualised
Bollinger upper
19.76
20, 2σ
Bollinger lower
13.56
20, 2σ
50 / 200 cross
Death
15.74 vs 18.00
Trend bias
Above 200
+5.80%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.12
Less volatile than market
Correlation to SPY
0.01
Largely independent
Realised vol 30D
102.5%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-93.2%
Peak to trough
Max drawdown 5Y
-97.4%
Peak to trough
ATR 14
1.59
8.34% of price
Beta (reported)
0.59
5Y monthly, from filing
Short interest
Shares short
1.59K
Prior 1.88K
Change vs prior
-15.4%
Shorts covering
% of float
0.08%
Normal
% of shares out
0.05%
Against total outstanding
Days to cover
0.1
Liquid
Float
1.76M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 9, 26 | Greenridge Global | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split1:20
Split dateMar 23, 2026
SEC filings
Corporate Changes & Voting Matters
6-K · 2026-09-29
Corporate Changes & Voting Matters
6-K · 2026-08-26
Offering Registrations
F-3/A · 2026-07-31
Corporate Changes & Voting Matters
6-K · 2026-07-28
Offering Registrations
F-3/A · 2026-07-17
Offering Registrations
F-3/A · 2026-07-07
Corporate Changes & Voting Matters
6-K · 2026-06-10
Corporate Changes & Voting Matters
6-K · 2026-06-01
Headlines
EUDA Health Subsidiary Melana International Wins SME100 Awards 2026 Singapore
GlobeNewswire · 42d ago
EUDA Health, GO POSB, Shenzhen Innovation Plan Cell Therapy Collaboration
MT Newswires · 69d ago
EUDA Health Announces Collaboration to Advance an Integrated iPSC Cell Therapy Program for Oncology and Wellness • Targets global distribution for innovative Oncology products
GlobeNewswire · 69d ago
EUDA Health Signs MOU With GO POSB Organoids, Shenzhen Inno on Induced Pluripotent Stem Cell Therapies
MT Newswires · 71d ago
EUDA Health Signs Important Tri-Party Memorandum of Understanding with GO POSB Organoids and Shenzhen Inno to Significantly Advance Next-Generation iPSC and NK-TCR Cell Therapies
GlobeNewswire · 71d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.